Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Pregnancy-Associated Aplastic Anemia.

IF 2.8 4区医学 Q3 HEMATOLOGY

Acta Haematologica Pub Date : 2026-03-13 DOI:10.1159/000551296

Xinxin Li, Liangliang Wu, Yumiao Li, Wenjian Mo, Xiaowei Chen, Ming Zhou, Ruiqing Zhou, Shilin Xu, Shiyi Pan, Caixia Wang, Shunqing Wang, Yuping Zhang

{"title":"Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Pregnancy-Associated Aplastic Anemia.","authors":"Xinxin Li, Liangliang Wu, Yumiao Li, Wenjian Mo, Xiaowei Chen, Ming Zhou, Ruiqing Zhou, Shilin Xu, Shiyi Pan, Caixia Wang, Shunqing Wang, Yuping Zhang","doi":"10.1159/000551296","DOIUrl":null,"url":null,"abstract":"Introduction: The prognosis and management of pregnancy-associated aplastic anemia (PAA) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain uncertain. This retrospective study was conducted to describe our clinical experience and to explore the efficacy and safety of allo-HSCT in patients with PAA.Methods: A retrospective observational study was evaluated the safety and feasibility of allo-HSCT in 18 patients with PAA who were treated between January 2013 and November 2023.Results: Median neutrophil engraftment occurred at 11.5 days (range: 6-15), and platelet engraftment occurred at 11.5 days (range: 7-28). The cumulative incidence (CuI) of both neutrophil and platelet engraftment was 100%. The CuI rates were 22.96% (95% CI, 13.68-27.32) for grade II acute graft-versus-host disease (aGVHD) and 12.61% (95% CI, 9.32-29.28) for chronic GVHD (cGVHD). No cases of grade III-IV aGVHD, extensive cGVHD, or relapse were observed. The CuI of transplantation-related mortality was 19.87% (95% CI, 13.15-30.73). Among the 15 surviving patients, the median follow-up was 47.0 months (range: 7.6-122.2 months). The overall survival and relapse/rejection-free rates were both 80.14% (95% CI, 69.27-86.86).Conclusion: These findings suggest that allo-HSCT is a viable and effective treatment option for PAA. The donor types included 8 matched sibling donors, 1 matched unrelated donor, 3 mismatched unrelated donors, and 6 haploidentical donors.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-14"},"PeriodicalIF":2.8000,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Haematologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000551296","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The prognosis and management of pregnancy-associated aplastic anemia (PAA) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain uncertain. This retrospective study was conducted to describe our clinical experience and to explore the efficacy and safety of allo-HSCT in patients with PAA.

Methods: A retrospective observational study was evaluated the safety and feasibility of allo-HSCT in 18 patients with PAA who were treated between January 2013 and November 2023.

Results: Median neutrophil engraftment occurred at 11.5 days (range: 6-15), and platelet engraftment occurred at 11.5 days (range: 7-28). The cumulative incidence (CuI) of both neutrophil and platelet engraftment was 100%. The CuI rates were 22.96% (95% CI, 13.68-27.32) for grade II acute graft-versus-host disease (aGVHD) and 12.61% (95% CI, 9.32-29.28) for chronic GVHD (cGVHD). No cases of grade III-IV aGVHD, extensive cGVHD, or relapse were observed. The CuI of transplantation-related mortality was 19.87% (95% CI, 13.15-30.73). Among the 15 surviving patients, the median follow-up was 47.0 months (range: 7.6-122.2 months). The overall survival and relapse/rejection-free rates were both 80.14% (95% CI, 69.27-86.86).

Conclusion: These findings suggest that allo-HSCT is a viable and effective treatment option for PAA. The donor types included 8 matched sibling donors, 1 matched unrelated donor, 3 mismatched unrelated donors, and 6 haploidentical donors.

查看原文本刊更多论文

异基因造血干细胞移植治疗妊娠相关性再生障碍性贫血的疗效。

同种异体造血干细胞移植（alloo - hsct）后妊娠相关性再生障碍性贫血（PAA）的预后和治疗仍不确定。本研究对2013年1月至2023年11月期间接受治疗的18例PAA患者进行了同种异体造血干细胞移植的安全性和可行性评估。供体类型包括8个匹配的兄弟姐妹供体，1个匹配的非亲属供体，3个不匹配的非亲属供体，6个单倍体相同的供体。中位中性粒细胞植入发生在11.5天（范围：6-15），血小板植入发生在11.5天（范围：7-28）。中性粒细胞和血小板植入的累积发生率均为100%。II级急性移植物抗宿主病（aGVHD）的CI为22.96%±10.10%，慢性移植物抗宿主病（cGVHD）的CI为12.61%±8.37%。未观察到III-IV级aGVHD、广泛性cGVHD或复发病例。移植相关死亡率CI为19.87%±10.49%。在15例存活患者中，中位随访时间为1409天（范围：228- 3666）。总生存率（OS）和无复发/无排斥反应（GRFS）均为80.14%±10.49%。这些发现表明，同种异体造血干细胞移植是治疗PAA的可行和有效的选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Haematologica 医学-血液学

CiteScore

4.90

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： ''Acta Haematologica'' is a well-established and internationally recognized clinically-oriented journal featuring balanced, wide-ranging coverage of current hematology research. A wealth of information on such problems as anemia, leukemia, lymphoma, multiple myeloma, hereditary disorders, blood coagulation, growth factors, hematopoiesis and differentiation is contained in first-rate basic and clinical papers some of which are accompanied by editorial comments by eminent experts. These are supplemented by short state-of-the-art communications, reviews and correspondence as well as occasional special issues devoted to ‘hot topics’ in hematology. These will keep the practicing hematologist well informed of the new developments in the field.